Novartis works tirelessly with third-party organizations to improve access to cancer care.

Novartis collaborates with Homology Medicines to adapt and refine genome editing technology.

Among the many Syrians uprooted by armed conflict are thousands of people with chronic conditions – such as diabetes and heart disease - whose treatment was disrupted when they fled.

Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.

A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.

Bringing healthcare closer to where people live, work and shop can effectively tackle hypertension – the most deadly noncommunicable disease.